. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2017 Jan 30;26(6):837–844. doi: 10.1158/1055-9965.EPI-16-0695

Table 4.

Reclassification of TP53 mutation carriers using LFSPRO.

	LFSPRO	Carriers		Non-carriers		Reclassification Rate^c
	LFSPRO	Pr≥0.2	Pr<0.2	Pr≥0.2	Pr<0.2	Reclassification Rate^c
MDACC	Classic
	+	4	0^b	0	1^a	11.0%
	-	16^a	12	14^b	234	11.0%
	Chompret
	+	11	3^b	3	11^a	12.1%
	-	9^a	9	11^b	224	12.1%

ISKS	Classic
	+	2	0^b	1	0^a	2.6%
	-	4^a	19	12^b	575	2.6%
	Chompret
	+	3	7^b	2	32^a	8.6%
	-	3^a	12	11^b	543	8.6%

NCI	Classic
	+	23	0^b	1	0^a	49.7%
	-	146^a	41	82^b	166	49.7%
	Chompret
	+	94	18^b	6	8^a	38.8%
	-	75^a	23	77^b	158	38.8%

LFSPRO corrected classifications of carrier or non-carrier, as compared to clinical criteria.

The clinical criteria corrected classifications of carrier or non-carrier, as compared to LFSPRO

Reclassification rate is defined as the percentage of individuals that were classified differently by LFSPRO (categories a and b) as compared with the other criteria.